Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.6652W HIGH $3.72
Volume
788.41 K
Value Traded
1.30 M
Short % Float
6.36%
Days to Cover
5.9
+4.86%Week
-31.27%1 Month
-18.81%3 Month
-35.16%6 Month
-89.09%5 Year
-94.47%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
130.36 M
EPS (TTM)
-1.64
P/E Ratio
-
Ent. Value
-52.05 M
Total Shares
71.62 M
Float Shares
57.57 M
Insiders
19.62%
Institutions
64.19%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
NKTX Catalyst Timeline
Dated clinical, regulatory and corporate events for Nkarta, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Nkarta, Inc.
284Total events
6Upcoming
34Tier-1 (high impact)
2018 to 2026Coverage
Upcoming catalysts 2
Event history 50
●Enrollment UpdateNKX101Trial
Enrollment continues across all indications in Ntrust-1 at 4 billion cell dose level
◆Oral PresentationPresentation
Nkarta President to participate in fireside chat at H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
B cell-mediated autoimmune diseasessource ↗
◆Enrollment UpdateNKX019Trial
Enrollment ongoing at 4 billion cell dose level across all indications in Ntrust-1
autoimmune diseasessource ↗
▲Protocol AmendmentNKX019Trial
IRB approval of protocol amendments for outpatient dosing, re-dosing, ending overnight monitoring, and adding RA
autoimmune diseasessource ↗
◆Oral PresentationPresentation
Nkarta CEO Paul Hastings panel discussion at Needham Virtual Healthcare Conference
▲FDA Feedback ReceivedNKX019FDA Meeting
FDA agreement on outpatient dosing and protocol amendments for NKX019 in Ntrust-1 and Ntrust-2
autoimmune diseasesource ↗
▲Protocol AmendmentNKX019Trial
Protocol amendment to enable outpatient dosing, redosing, and add rheumatoid arthritis cohort in Ntrust-2
autoimmune diseasesource ↗
▲FDA Feedback ReceivedNKX019FDA Meeting
FDA agreement to amend protocol for outpatient dosing, re-dosing, removal of overnight monitoring, and expansion of Ntrust-2 to include rheumatoid arthritis
autoimmune diseasessource ↗
▲Enrollment UpdateNKX019Trial
Dosing patients at 4 billion cells in a three-dose cycle for Ntrust-1
autoimmune diseasessource ↗
▲Runway Guidance UpdateCorporate
Cash balance of $295.1 million expected to fund operations into 2029
▲Dose Finding UpdateNKX019Trial
Dose escalation advanced to 4 billion cells per dose on days 0, 3 and 7
autoimmune diseasessource ↗
◆Oral PresentationPresentation
Nkarta to participate in Evercore 8th Annual Healthcare Conference fireside chat
◆Poster PresentationNKX019Presentation
Poster presentation at ACR Convergence 2025: NKX019 induces deep CD19+ B cell depletion in hematological malignancy and models of autoimmune disease
non-Hodgkin lymphoma; B-cell driven autoimmune diseasessource ↗
▲FDA Feedback ReceivedNKX019FDA Meeting
FDA clearance of study design modifications including combined iDSMB, removal of patient stagger, and new lymphodepletion regimen
autoimmune diseasessource ↗
▲Enrollment MilestoneNKX019Trial
iDSMB authorized initiation of second dose-escalation cohort
autoimmune diseasessource ↗
◆Oral PresentationPresentation
Participation in H.C. Wainwright 27th Annual Global Investment Conference
▲Management ChangeCorporate
Appointment of Shawn Rose, M.D., Ph.D. as Chief Medical Officer and Head of R&D
▲Enrollment CompleteNKX019Trial
Enrollment open in IST of NKX019 in systemic lupus erythematosus
systemic lupus erythematosussource ↗
▲Enrollment UpdateNKX019Trial
Ntrust-1 expanded to include primary membranous nephropathy cohort
lupus nephritissource ↗
●Protocol AmendmentNKX019Trial
Lymphodepletion regimen modified to include fludarabine and cyclophosphamide
autoimmune diseasessource ↗
◆Oral PresentationPresentation
Participation in 24th Annual Needham Virtual Healthcare Conference
◆Topline ReadoutNKX019Clinical Data
Preliminary data from Ntrust-1 and Ntrust-2 expected in H2 2025
autoimmune diseases (lupus nephritis, primary membranous nephropathy, systemic sclerosis, idiopathic inflammatory myopathy, ANCA-associated vasculitis)source ↗
◆Topline ReadoutNKX019Clinical Data
Preliminary data from Ntrust-1 and Ntrust-2 anticipated
lupus nephritis, systemic sclerosis, myositis, ANCA-associated vasculitissource ↗
◆Trial InitiationNKX019Trial
Enrollment initiation expected for Ntrust-2 trial by year-end 2024
systemic sclerosis, myositis, vasculitissource ↗
▲IND ClearanceNKX019IND
IND clearance for IST of NKX019 in myasthenia gravis
myasthenia gravissource ↗
▲Enrollment MilestoneNKX019Trial
Opening of enrollment for Ntrust-2
systemic sclerosis, myositis, ANCA-associated vasculitissource ↗
▲First Patient DosedNKX019Trial
First patient dosed in IST of NKX019 for SLE
systemic lupus erythematosussource ↗
▲Enrollment UpdateNKX019Trial
Opening of enrollment for Ntrust-2 trial of NKX019
systemic sclerosis, idiopathic inflammatory myopathy, ANCA-associated vasculitissource ↗
Past FDA Catalysts and PDUFA Decisions
How NKTX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | NKX019 | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 36%
Micro Cap(rank 237 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NKX019 Monoclonal antibodyNCT05020678 | Lymphoma, Non-Hodgkin | Phase 1 | ACTIVE NOT_RECRUITING | 150 | Dec 1, 2038 | ||||||
| NKX019 Small moleculeNCT06733935 | Systemic Sclerosis | Phase 1 | RECRUITING | 240 | Oct 1, 2028 | ||||||
| NKX019 Small moleculeNCT06557265 | Lupus Nephritis | Phase 1 | RECRUITING | 120 | Apr 1, 2027 | ||||||
| NKX101 Cell therapyNCT04623944 | Relapsed/Refractory AML | Phase 1 | ACTIVE NOT_RECRUITING | 61 | Jul 1, 2039 |
Clinical Trial Results
Readouts, endpoints and source filings for every NKTX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| NKX101 | relapsed or refractory acute myeloid leukemia (r/r AML) | Phase 1 | 2023-12-10 | three out of four patients who initially achieved complete responses maintained those responses four months after treatment; four of six achieved CR/CRiRead More | Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & ExpositionRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| HASTINGS PAUL JDirector, Officer (Chief Executive Officer) | Sell | -1,776 390,247 held | $2.71 | 06/18/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NKTX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 0.3 % (50 %) | 30.58 M | 10.81 M |
NKTX Institutional Ownership Trends
NKTX Short Interest
Shares sold short, counted twice a month.
6.36%
Short % of Float
of tradable shares sold short
3.7M
Shares Sold Short
+4.4% vs prior count
5.9 High
Days to Cover
trading days of normal volume to buy every short share back
621.7K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NKTX ranks across every disease it competes in
Competitive Position is a premium feature
See how NKTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNKTX News
NKTXNkarta to Participate in September Investor Conferences
Nkarta, Inc. announced its participation in two upcoming investor conferences in September 2026. The events include the H.C. Wainwright 28th Annual Global Investment Conference and the Stifel 2026 Virtual Immunology and Inflammation Forum. Nkarta focuses on developing engineered NK cell therapies for autoimmune diseases, providing accessible treatment options.
Read more →NKTX▲ +10.6%on this newsshared move
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
Nkarta, Inc. announced its selection for three presentations at ACR Convergence 2026, showcasing initial clinical data for NKX019, an investigational CAR-NK cell therapy. The presentations will highlight the therapy's safety and clinical activity in idiopathic inflammatory myopathy and systemic sclerosis. CEO Paul J. Hastings emphasized the potential of NKX019 to improve patient access to treatment.
Read more →NKTX▼ -5.3%on this news
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights
Nkarta has reported its financial results for the second quarter of 2026, highlighting ongoing enrollment in its Ntrust-1 and Ntrust-2 clinical trials at a high cell dose level. The company anticipates presenting initial clinical data from these trials at a medical conference in 2026. As of June 30, 2026, Nkarta's cash balance stands at $243.2 million.
Read more →NKTXNkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
Nkarta, Inc. will participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30th. President Nadir Mahmood will discuss the company's investigational CAR-NK cell therapy targeting B cell-mediated autoimmune diseases. The event will be available via webcast and archived for 90 days.
Read more →NKTXNkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
Nkarta, Inc. reported its Q1 2026 financial results, highlighting ongoing enrollment in clinical trials Ntrust-1 and Ntrust-2 for NKX019, an engineered NK cell therapy for autoimmune diseases. A regulatory agreement allows outpatient dosing to improve patient access. The company has a cash balance of $266.7 million, expected to sustain operations until 2029, with initial clinical data projected for release in 2026.
Read more →NKTX▲ +5.7%on this news· ran to +52% by day 3shared move
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
Nkarta, Inc. has reached an agreement with the FDA to implement outpatient dosing for its investigational CAR-NK cell therapy, NKX019, in ongoing clinical trials Ntrust-1 and Ntrust-2. This change aims to reduce patient burden by minimizing monitoring time and expanding access through community rheumatology centers. The trials will also include a cohort for rheumatoid arthritis, enhancing the scope of treatment.
Read more →NKTXNkarta to Participate in Needham Virtual Healthcare Conference
Nkarta, Inc. will participate in the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. CEO Paul Hastings will join a panel discussion on cell therapy in autoimmune diseases, while President Nadir Mahmood will provide updates on their investigational CAR-NK cell therapy. The event will be accessible via webcast.
Read more →NKTXNkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights
Nkarta, Inc. reported its financial results for Q4 and the full year 2025, highlighting advancements in its NKX019 clinical program. The company has escalated dosing to 4 billion cells and plans to present initial clinical data from its Ntrust trials in 2026. Despite a net loss of $104.1 million, Nkarta's cash reserves are projected to sustain operations until 2029.
Read more →NKTXNkarta to Participate in March Investor Conferences
Nkarta, Inc. announced its participation in two upcoming investor conferences in March 2026. The events include the TD Cowen 46th Annual Health Care Conference and the Leerink Global Healthcare Conference, where Nkarta will host fireside chats. Both events will be available via webcast, enhancing accessibility for investors.
Read more →NKTXNkarta to Participate in Evercore Healthcare Conference 2025
Nkarta, Inc. will participate in the Evercore 8th Annual Healthcare Conference on December 4, 2025. The event will feature a fireside chat at 10:50 a.m. ET and will be available via a webcast. Nkarta focuses on developing engineered NK cell therapies aimed at treating autoimmune diseases, enhancing outpatient treatment accessibility.
Read more →NKTXNkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights
Nkarta reported a net loss of $21.7 million for the third quarter of 2025. The company held $316.5 million in cash and investments as of September 30. Enrollment has begun in the second dose-escalation cohort for its NKX019 autoimmune therapy trials. Initial clinical data is expected to be presented at a medical conference in 2026.
Read more →NKTXNkarta to Participate in November Investor Conferences
Nkarta, Inc. has announced its participation in two upcoming investor conferences in November 2025. The events include a fireside chat at the Stifel 2025 Healthcare Conference on November 12 and another at TD Cowen’s Immunology & Inflammation Summit on November 13. A webcast of these events will be available on their website.
Read more →NKTXNkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting
Nkarta, Inc. will present clinical data on its investigational therapy NKX019 at the ACR Convergence 2025 meeting. The data indicates NKX019 effectively depletes pathogenic B cells, showing potential for treating autoimmune diseases. The presentation will take place on October 26, with additional information available at their booth.
Read more →NKTXNkarta to Participate in a September Investor Conference
Nkarta, Inc. announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 2025. The company will present a fireside chat, accessible via a live webcast and archived on their website for 90 days. Nkarta focuses on developing engineered natural killer (NK) cell therapies aimed at treating autoimmune diseases, utilizing advanced cell engineering technologies. This event highlights the company's progress and commitment to innovation in biopharmaceuticals.
Read more →NKTXNkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights
Nkarta, Inc. reported its second quarter 2025 financial results, noting a cash balance of $334 million that is anticipated to fund operations through 2029. The company continues to advance its clinical trials for NKX019, with initial updates expected in the latter half of 2025 for various autoimmune conditions. Despite a net loss of $23 million, the appointment of Dr. Shawn Rose as CMO is expected to bolster Nkarta’s clinical efforts in autoimmune therapies. Ongoing trials include Ntrust-1 and Ntrust-2, focusing on safety and efficacy in autoimmune disease treatment.
Read more →NKTX▲ +7.2%on this news
Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series
Nkarta, Inc. announced its participation in the H.C. Wainwright 'HCW@Home' Series, scheduled for July 30, 2025. The event will feature a fireside chat at 11:00 a.m. ET, and a webcast will be available for those unable to attend live. Nkarta is focused on developing engineered NK cell therapies for autoimmune diseases.
Read more →NKTXNkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus
Nkarta, Inc. has appointed Dr. Shawn Rose as Chief Medical Officer and Head of R&D, effective June 23, 2025. He replaces Dr. David Shook, who is leaving to pursue opportunities in oncology. Dr. Rose brings extensive experience in immunology and has a history of advancing clinical programs. His leadership is expected to enhance Nkarta's efforts in developing NK cell therapies for autoimmune diseases.
Read more →NKTXNkarta Reports First Quarter 2025 Financial Results and Corporate Highlights
Nkarta, Inc. has reported its financial results for the first quarter of 2025, highlighting the opening of enrollment for several investigator-sponsored trials of NKX019. The company plans to utilize a modified lymphodepletion regimen to enhance the efficacy of its trials. Despite facing a net loss of $32 million, Nkarta maintains a robust cash balance of $351.9 million, which it expects will support operations through 2029. The trials aim to provide initial clinical data in the second half of 2025, potentially addressing unmet needs in various autoimmune diseases.
Read more →NKTXNkarta to Participate in an April Investor Conference
Nkarta, Inc. has announced its participation in an upcoming investor conference, which will be accessible via a webcast. The company focuses on developing engineered NK cell therapies for autoimmune diseases, utilizing advanced technologies like CRISPR. A replay of the event will be available on their website for 90 days.
Read more →NKTXNkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
Nkarta, Inc. announced its financial results for the fourth quarter and full year 2024, highlighting a restructured development program for NKX019 in autoimmune diseases. The company projects that its cash reserves will sustain operations through 2029 despite a workforce reduction of 34% to extend its cash runway. Initial clinical data from two ongoing trials is expected in late 2025, showcasing Nkarta's commitment to advancing CAR NK cell therapies despite facing challenges, including significant financial losses.
Read more →About Nkarta, Inc.
Headquarters1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080
BIOPHARMAWATCH ELITE PLUS
Trade the next NKTX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime